Trial Profile
A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Laronidase (Primary)
- Indications Lysosomal storage diseases; Mucopolysaccharidosis I
- Focus Adverse reactions
- 25 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jun 2014 New trial record